Stability and Preservation of a New Formulation of Epoprostenol Sodium for Treatment of Pulmonary Arterial Hypertension

Drug Design, Development and Therapy - New Zealand
doi 10.2147/dddt.s31628
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients With Pulmonary Arterial Hypertension (EPITOME4)

Advances in Therapy
MedicinePharmacology
2013English

Erratum To: Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients With a Pulmonary Arterial Hypertension (EPITOME4)

Advances in Therapy
MedicinePharmacology
2013English

Epoprostenol Treatment for Idiopathic Pulmonary Arterial Hypertension in Pregnancy

Journal of Perinatology
GynecologyChild HealthPediatricsPerinatologyObstetrics
2010English

Stability and Microbiological Properties of a New Formulation of Epoprostenol Sodium When Reconstituted and Diluted

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2012English

Withdrawal of Long-Term Epoprostenol Therapy in Pulmonary Arterial Hypertension (PAH)

Pulmonary Circulation
PulmonaryRespiratory Medicine
2017English

Continuous Intravenous Epoprostenol for Pulmonary Arterial Hypertension: Highlighting Practical Issues, Special Considerations

Advances in Pulmonary Hypertension
2002English

Epoprostenol Treatment in Children With Severe Pulmonary Hypertension

Heart
Cardiovascular MedicineCardiology
2007English

Surgical Treatment of Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2010English

A Pharmaceutical Formulation and Evaluation of a Cardiovascular Drug for Improving Pulmonary Arterial Hypertension

International Journal of Biology, Pharmacy and Allied Sciences
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy